CLINICAL ETHICS CHARTER DECLARATION OF HELSINKI COMPLIANT • Double-Blind Editorial Oversight

Academic Integrity & Editorial Governance

Rigorous ethical standards, double-blind evaluation protocols, conflict of interest disclosures, and clinical trial reporting standards across ADC-RadCon 2027.

PEER REVIEW MODEL Double-Blind Review
EVALUATION CYCLE Rolling 10-Day Cycle
ETHICAL CHARTER Declaration of Helsinki
FACULTY DISCLOSURE Mandatory COI Registry
Editorial Governance

Translational Rigor & Peer Review Safeguards

Protecting oncology research authenticity, clinical dosimetry integrity, and patient trial welfare.

Precision oncology therapeutics and targeted alpha radiopharmaceuticals demand the highest standard of scientific integrity. Because findings presented at ADC-RadCon 2027 directly inform early-phase bedside trials and patient dosimetry models, all abstracts undergo double-blind peer review.

Submitted manuscripts are assessed by an independent academic steering committee with author names, commercial affiliations, and institutional origins masked during initial scoring to eliminate bias.

Plagiarism, data fabrication, uncredited re-use of published figures, or redundant publication will result in immediate desk rejection and formal notification to the corresponding author's institutional oversight office.

Editorial Mandates

  • Mandatory IRB / Ethics Committee approval on all human clinical trial datasets.
  • Preclinical animal cohorts must verify certified animal welfare guidelines.
  • Authors must declare all biopharma consulting honoraria and
Scroll to Top